Naked DNA Malaria Vaccine Enters Trials
Vical and Pasteur Merieux Connaught have started a Phase I trial of aDNA vaccine against the Plasmodium parasite that causes malaria. The trial is being conducted by the US Naval Medical Research Institute and Army Research Institute of Infectious Diseases.
Naked DNA vaccines have advantages over traditional vaccines in that they can offer protection against multiple strains of an infectious agent, can be manufactured in bulk easily and offer greater safety than virus-based vaccines. Vical's first vaccine product, for influenza and partnered with Merck & Co, began trials last year.
The start of the malaria trial, the first in Vical's collaboration with PMC which spans six disease targets, prompts a $1 million milestone payment to Vical.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze